Skip to content

Multivisceral Resections for Locally Advanced Gastric Cancer

Multivisceral Resections for Locally Advanced Gastric Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06103435
Acronym
TOCCATA
Enrollment
1476
Registered
2023-10-26
Start date
1996-01-31
Completion date
2020-12-31
Last updated
2023-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Keywords

gastric cancer, locally advanced cancers, multivisceral resections, splenectomy, pancreatectomy, colectomy

Brief summary

The goal of this observational study is to assess whether the postoperative course and survival of patients subject to multivisceral resections for locally advanced gastric cancer (cT4b) were affected by the extent of surgery. An electronic database of 1476 patients with non-metastatic gastric cancer treated between January 1996 and December 2020 will be reviewed. The main questions it aims to answer are: * Does splenectomy, distal pancreatectomy or partial colectomy affect postoperative complications * What factors affect prognosis of patients with locally advanced gastric cancer

Interventions

PROCEDUREExtent od surgical resection

Sponsors

Jagiellonian University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

* gastric adenocarcinoma * intraoperatively suspected infiltration of surrounding organs (stage cT4bN0-3bM0) * partial or total gastrectomy

Exclusion criteria

* distant metastases (M1) * gastrectomy combined with resection of organs other than spleen, pancreas, or colon

Design outcomes

Primary

MeasureTime frameDescription
Complicationsup to 90 daysType and severity of complications graded by Clavien-Dindo scoring system (from 0 to 5, higher scores mean worse outcome)
SurvivalOverall survival from surgery to death or last follow up, whichever came first, assessed up to 60 monthsOverall survival

Secondary

MeasureTime frameDescription
Rate of reoperationsup to 90 daysReoperations
Length of postoperative hospital stayUp to 6 monthsHospital stay
Rate of readmissionsOne year from surgeryReadmission

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026